Cargando…
The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)
There is growing evidence that phagocytosis regulatory factors (PRFs) play important roles in tumor progression, and therefore, identifying and characterizing these factors is crucial for understanding the mechanisms of cellular phagocytosis in tumorigenesis. Our research aimed to comprehensively ch...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190300/ https://www.ncbi.nlm.nih.gov/pubmed/35706452 http://dx.doi.org/10.3389/fgene.2022.877278 |
_version_ | 1784725757467033600 |
---|---|
author | Xin, Shiyong Sun, Xianchao Jin, Liang Li, Weiyi Liu, Xiang Zhou, Liqing Ye, Lin |
author_facet | Xin, Shiyong Sun, Xianchao Jin, Liang Li, Weiyi Liu, Xiang Zhou, Liqing Ye, Lin |
author_sort | Xin, Shiyong |
collection | PubMed |
description | There is growing evidence that phagocytosis regulatory factors (PRFs) play important roles in tumor progression, and therefore, identifying and characterizing these factors is crucial for understanding the mechanisms of cellular phagocytosis in tumorigenesis. Our research aimed to comprehensively characterize PRFs in prostate adenocarcinoma (PRAD) and to screen and determine important PRFs in PRAD which may help to inform tumor prognostic and therapeutic signatures based on these key PRFs. Here, we first systematically described the expression of PRFs in PRAD and evaluated their expression patterns and their prognostic value. We then analyzed prognostic phagocytic factors by Cox and Lasso analysis and constructed a phagocytic factor-mediated risk score. We then divided the samples into two groups with significant differences in overall survival (OS) based on the risk score. Then, we performed correlation analysis between the risk score and clinical features, immune infiltration levels, immune characteristics, immune checkpoint expression, IC50 of several classical sensitive drugs, and immunotherapy efficacy. Finally, the Human Protein Atlas (HPA) database was used to determine the protein expression of 18 PRF characteristic genes. The aforementioned results confirmed that multilayer alterations of PRFs were associated with the prognosis of patients with PRAD and the degree of macrophage infiltration. These findings may provide us with potential new therapies for PRAD. |
format | Online Article Text |
id | pubmed-9190300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91903002022-06-14 The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD) Xin, Shiyong Sun, Xianchao Jin, Liang Li, Weiyi Liu, Xiang Zhou, Liqing Ye, Lin Front Genet Genetics There is growing evidence that phagocytosis regulatory factors (PRFs) play important roles in tumor progression, and therefore, identifying and characterizing these factors is crucial for understanding the mechanisms of cellular phagocytosis in tumorigenesis. Our research aimed to comprehensively characterize PRFs in prostate adenocarcinoma (PRAD) and to screen and determine important PRFs in PRAD which may help to inform tumor prognostic and therapeutic signatures based on these key PRFs. Here, we first systematically described the expression of PRFs in PRAD and evaluated their expression patterns and their prognostic value. We then analyzed prognostic phagocytic factors by Cox and Lasso analysis and constructed a phagocytic factor-mediated risk score. We then divided the samples into two groups with significant differences in overall survival (OS) based on the risk score. Then, we performed correlation analysis between the risk score and clinical features, immune infiltration levels, immune characteristics, immune checkpoint expression, IC50 of several classical sensitive drugs, and immunotherapy efficacy. Finally, the Human Protein Atlas (HPA) database was used to determine the protein expression of 18 PRF characteristic genes. The aforementioned results confirmed that multilayer alterations of PRFs were associated with the prognosis of patients with PRAD and the degree of macrophage infiltration. These findings may provide us with potential new therapies for PRAD. Frontiers Media S.A. 2022-05-30 /pmc/articles/PMC9190300/ /pubmed/35706452 http://dx.doi.org/10.3389/fgene.2022.877278 Text en Copyright © 2022 Xin, Sun, Jin, Li, Liu, Zhou and Ye. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Xin, Shiyong Sun, Xianchao Jin, Liang Li, Weiyi Liu, Xiang Zhou, Liqing Ye, Lin The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD) |
title | The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD) |
title_full | The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD) |
title_fullStr | The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD) |
title_full_unstemmed | The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD) |
title_short | The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD) |
title_sort | prognostic signature and therapeutic value of phagocytic regulatory factors in prostate adenocarcinoma (prad) |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190300/ https://www.ncbi.nlm.nih.gov/pubmed/35706452 http://dx.doi.org/10.3389/fgene.2022.877278 |
work_keys_str_mv | AT xinshiyong theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT sunxianchao theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT jinliang theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT liweiyi theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT liuxiang theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT zhouliqing theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT yelin theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT xinshiyong prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT sunxianchao prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT jinliang prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT liweiyi prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT liuxiang prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT zhouliqing prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad AT yelin prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad |